Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

In a quiet week for approvals from the US Food and Drug Administration, Novartis AG’s slow-growing blockbuster heart drug Entresto gained an expanded indication in heart failure.

The FDA’s popular Real-Time Oncology Review (RTOR) pilot program grew by two after Seagen Inc. and Astellas Pharma,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

More from Product Reviews